Results
13
Smaller, under-the-radar companies, backed by insider buying, presenting a compelling opportunity for investors seeking undervalued gems.
13 companies
Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | Industry | ||
---|---|---|---|---|---|---|---|---|---|---|---|
HLS | AU$1.42 | -0.4% | -52.5% | AU$1.0b | AU$1.41 | PB1x | E91.1% | 0% | Healthcare | ||
REP | AU$0.64 | 4.1% | -9.9% | AU$325.6m | n/a | PB1.4x | E112.0% | 8.4% | Real Estate | ||
DDR | AU$10.37 | 8.1% | 23.3% | AU$1.9b | AU$10.79 | PE22.8x | E7.8% | 4.3% | Tech | ||
CDA | AU$12.42 | 3.3% | 51.3% | AU$2.3b | AU$11.42 | PE30.1x | E16.2% | 1.6% | Tech | ||
ELD | AU$9.08 | 0% | 29.5% | AU$1.4b | AU$8.83 | PE22.6x | E22.8% | 4.0% | Food, Beverage & Tobacco | ||
CYG | AU$1.39 | 4.9% | 21.9% | AU$162.3m | AU$2.00 | PE291.5x | E82.3% | 2.5% | Capital Goods | ||
APE | AU$10.40 | 3.9% | -26.3% | AU$2.7b | AU$11.96 | PE9.6x | E-0.7% | 7.1% | Retail | ||
NEU | AU$15.60 | -8.7% | 25.9% | AU$2.0b | AU$26.54 | PE12.7x | E-7.6% | n/a | Pharmaceuticals & Biotech | ||
DRR | AU$3.69 | -2.6% | -18.0% | AU$2.0b | AU$4.49 | PE11.6x | E-8.0% | 8.6% | Materials | ||
KLS | AU$5.05 | 0.6% | -25.5% | AU$1.4b | AU$7.04 | PE46x | E25.5% | 3.5% | Transportation | ||
MFF | AU$3.76 | -0.3% | 31.0% | AU$2.2b | n/a | PE4.9x | n/a | 3.7% | Diversified Financials | ||
ACF | AU$1.07 | -1.4% | 21.6% | AU$322.5m | AU$1.36 | PE12.8x | E18.6% | 5.3% | Capital Goods | ||
PPS | AU$0.43 | -8.5% | -27.1% | AU$207.3m | n/a | PE20.6x | E19.5% | n/a | Software |